Displaying drugs 11526 - 11550 of 12789 in total
DTX-101
DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene. It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.
Investigational
BBM-H803
BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed. It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.
Investigational
WP-1301
WP1301 is a synthetic peptide derived from hFVIII. It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.
Investigational
Coagulin-B
Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX.[A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation.
Investigational
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
MaxAdFVIII
MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Investigational
Thalagen
Thalagen is a branded product developed by San Rocco Therapeutics. It consists of autologous CD34-positive hematopoietic progenitor cells transduced with TNS9.3.55, a lentiviral vector encoding the normal human beta-globin gene. It is being investigated for the treatment of beta-thalassemia.
Investigational
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Vensobafusp alfa
Experimental
NM3086
NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.
Experimental
RLYB212
RLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Investigational
Valziflocept
Investigational
Recombinant Factor XIII (human)
Investigational
Tubimod
Investigational
Staphylococcus aureus immune globulin (human)
Investigational
MCMV5322A
MCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with MCMV3068A to form RG7667.
Investigational
Zamerovimab
Investigational
EF-022
EF-022 is a modified version of vitamin D binding protein macrophage activator, with potential antineoplastic and anti-angiogenic activities.
Investigational
MBL-HCV1
MBL-HCV1 is a monoclonal antibody developed to prevent the recurrence of hepatitis C virus (HCV) in patients receiving a liver transplant.
Investigational
Recombinant soluble human CD4
Investigational
Cryptosporidium immune globulin
Investigational
Octovalent O-polysaccharide-toxin A conjugate vaccine
Octovalent O-polysaccharide-toxin A conjugate vaccine is currently being investigated to treat Pseudomonas Aeruginosa infection in patients with cystic fibrosis.
Investigational
BAL200
Investigational
Puumala virus DNA vaccine
Investigational
Recombinant human CD4 immunoglobulin G
Investigational
Displaying drugs 11526 - 11550 of 12789 in total